{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T22:15:43Z","timestamp":1774649743863,"version":"3.50.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T00:00:00Z","timestamp":1674950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T00:00:00Z","timestamp":1674950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/PR15284\/MED\/29\/291\/2011"],"award-info":[{"award-number":["BT\/PR15284\/MED\/29\/291\/2011"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["3\/1\/3\/JRF-2018\/HRD-066(66125)"],"award-info":[{"award-number":["3\/1\/3\/JRF-2018\/HRD-066(66125)"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>No commercial vaccines are available against drug-resistant <jats:italic>Shigella<\/jats:italic> due to serotype-specific\/narrow-range of protection. Nanoparticle-based biomimetic vaccines involving stable, conserved, immunogenic proteins fabricated using facile chemistries can help formulate a translatable cross-protective <jats:italic>Shigella<\/jats:italic> vaccine. Such systems can also negate cold-chain transportation\/storage thus overcoming challenges prevalent in various settings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We explored facile development of biomimetic poly (lactide-<jats:italic>co<\/jats:italic>-glycolide)\/PLGA 50:50 based nanovaccines (NVs), encapsulating conserved stabilized antigen(s)\/immunostimulant of <jats:italic>S. dysenteriae<\/jats:italic> 1 origin surface-modified using simple chemistries. All encapsulants (IpaC\/IpaB\/LPS) and nanoparticles (NPs)\u2014bare and modified (NV), were thoroughly characterized. Effect of IpaC on cellular uptake of NPs was assessed in-vitro. Immunogenicity of the NVs was assessed in-vivo in BALB\/c mice by intranasal immunization. Cross-protective efficacy was assessed by intraperitoneally challenging the immunized groups with a high dose of heterologous <jats:italic>S. flexneri<\/jats:italic> 2a and observing for visible diarrhea, weight loss and survival. Passive-protective ability of the simplest NV was assessed in the 5-day old progeny of vaccinated mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All the antigens and immunostimulant to be encapsulated were successfully purified and found to be stable both before and after encapsulation into NPs. The ~\u2009300\u00a0nm sized NPs with a zeta potential of ~\u2009\u2212\u00a025\u00a0mV released ~\u200960% antigen by 14th day suggesting an appropriate delivery kinetics. The NPs could be successfully surface-modified with IpaC and\/or CpG DNA. <jats:italic>In\u00a0vitro<\/jats:italic> experiments revealed that the presence of IpaC can significantly increase cellular uptake of NPs. All NVs were found to be cytocompatible and highly immunogenic. Antibodies in sera of NV-immunized mice could recognize heterologous <jats:italic>Shigella<\/jats:italic>. Immunized sera also showed\u00a0high antibody and cytokine response. The immunized groups were protected from diarrhea and weight loss with ~\u200970\u201380% survival upon heterologous <jats:italic>Shigella<\/jats:italic> challenge. The simplest NV showed ~\u200988% survival in neonates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Facile formulation of biomimetic NVs can result in significant cross-protection. Further, passive protection in neonates suggest that parental immunization could protect infants, the most vulnerable group in context of <jats:italic>Shigella<\/jats:italic> infection. Non-invasive route of vaccination can also lead to greater patient compliance making it amenable for mass-immunization. Overall, our work contributes towards a yet to be reported platform technology for facile development of cross-protective <jats:italic>Shigella<\/jats:italic> vaccines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s12951-023-01780-y","type":"journal-article","created":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T13:02:46Z","timestamp":1674997366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Facile synthesis of multi-faceted, biomimetic and cross-protective nanoparticle-based vaccines for drug-resistant Shigella: a flexible platform technology"],"prefix":"10.1186","volume":"21","author":[{"given":"Namrata","family":"Baruah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadim","family":"Ahamad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prolay","family":"Halder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemanta","family":"Koley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhirendra S.","family":"Katti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,29]]},"reference":[{"key":"1780_CR1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S1473-3099(17)30276-1","volume":"17","author":"C Troeger","year":"2017","unstructured":"Troeger C, Forouzanfar M, Rao PC, Khalil I, Brown A, Reiner RC Jr, Fullman N, Thompson RL, Abajobir A, Ahmed M. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17:909\u201348.","journal-title":"Lancet Infect Dis"},{"key":"1780_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0140-6736(17)33296-8","volume":"391","author":"KL Kotloff","year":"2018","unstructured":"Kotloff KL, Riddle MS, Platts-Mills JA, Pavlinac P, Zaidi AK. Shigellosis. The Lancet. 2018;391:801\u201312.","journal-title":"The Lancet"},{"key":"1780_CR3","first-page":"133","volume":"43","author":"SK Niyogi","year":"2005","unstructured":"Niyogi SK. Shigellosis. J Microbiol. 2005;43:133\u201343.","journal-title":"J Microbiol"},{"key":"1780_CR4","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/S1473-3099(18)30475-4","volume":"18","author":"IA Khalil","year":"2018","unstructured":"Khalil IA, Troeger C, Blacker BF, Rao PC, Brown A, Atherly DE, Brewer TG, Engmann CM, Houpt ER, Kang G. Morbidity and mortality due to Shigella and enterotoxigenic Escherichia coli diarrhoea: the global burden of disease study 1990\u20132016. Lancet Infect Dis. 2018;18:1229\u201340.","journal-title":"Lancet Infect Dis"},{"key":"1780_CR5","doi-asserted-by":"publisher","DOI":"10.1053\/j.spid.2005.12.008","author":"M O\u2019Ryan","year":"2005","unstructured":"O\u2019Ryan M, Prado V, Pickering LK. A millennium update on pediatric diarrheal illness in the developing world. Semin Pediatr Infect Dis. 2005. https:\/\/doi.org\/10.1053\/j.spid.2005.12.008.","journal-title":"Semin Pediatr Infect Dis"},{"key":"1780_CR6","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1128\/AAC.49.2.816-819.2005","volume":"49","author":"TV Nguyen","year":"2005","unstructured":"Nguyen TV, Van Le P, Le CH, Weintraub A. Antibiotic resistance in diarrheagenic Escherichia coli and Shigella strains isolated from children in Hanoi, Vietnam. Antimicrob Agents Chemother. 2005;49:816\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1780_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jiph.2017.09.025","volume":"11","author":"M Puzari","year":"2018","unstructured":"Puzari M, Sharma M, Chetia P. Emergence of antibiotic resistant Shigella species: a matter of concern. J Infect Public Health. 2018;11:451\u20134.","journal-title":"J Infect Public Health"},{"key":"1780_CR8","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/infdis\/162.6.1324","volume":"162","author":"M Wharton","year":"1990","unstructured":"Wharton M, Spiegel RA, Horan JM, Tauxe RV, Wells JG, Barg N, Herndon J, Meriwether RA, MacCormack JN, Levine R. A large outbreak of antibiotic-resistant shigellosis at a mass gathering. J Infect Dis. 1990;162:1324\u20138.","journal-title":"J Infect Dis"},{"key":"1780_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3201\/eid2302.161203","volume":"23","author":"K Murray","year":"2017","unstructured":"Murray K, Reddy V, Kornblum JS, Waechter H, Chicaiza LF, Rubinstein I, Balter S, Greene SK, Braunstein SL, Rakeman JL. Increasing antibiotic resistance in Shigella spp. from infected New York City residents, New York, USA. Emer Infect Dis. 2017;23:332.","journal-title":"Emer Infect Dis"},{"key":"1780_CR10","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3855\/jidc.560","volume":"3","author":"R Ranjbar","year":"2009","unstructured":"Ranjbar R, Soltan-Dallal MM, Pourshafie MR, Mammina C. Antibiotic resistance among Shigella serogroups isolated in Tehran, Iran (2002\u20132004). J Infect Dev Ctries. 2009;3:647\u20138.","journal-title":"J Infect Dev Ctries"},{"key":"1780_CR11","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1017\/S0950268814000958","volume":"143","author":"D Bhattacharya","year":"2015","unstructured":"Bhattacharya D, Bhattacharya H, Sayi D, Bharadwaj A, Singhania M, Sugunan A, Roy S. Changing patterns and widening of antibiotic resistance in Shigella spp. over a decade (2000\u20132011), Andaman Islands, India. Epidemiol Infect. 2015;143:470\u20137.","journal-title":"Epidemiol Infect"},{"key":"1780_CR12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1099\/jmm.0.2008\/000521-0","volume":"57","author":"GP Pazhani","year":"2008","unstructured":"Pazhani GP, Niyogi SK, Singh AK, Sen B, Taneja N, Kundu M, Yamasaki S, Ramamurthy T. Molecular characterization of multidrug-resistant Shigella species isolated from epidemic and endemic cases of shigellosis in India. J Med Microbiol. 2008;57:856\u201363.","journal-title":"J Med Microbiol"},{"key":"1780_CR13","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1016\/j.vaccine.2016.02.075","volume":"34","author":"S Mani","year":"2016","unstructured":"Mani S, Wierzba T, Walker RI. Status of vaccine research and development for Shigella. Vaccine. 2016;34:2887\u201394.","journal-title":"Vaccine"},{"key":"1780_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1586\/erv.12.135","volume":"12","author":"AI Camacho","year":"2013","unstructured":"Camacho AI, Irache JM, Gamazo C. Recent progress towards development of a Shigella vaccine. Expert Rev Vaccines. 2013;12:43\u201355.","journal-title":"Expert Rev Vaccines"},{"key":"1780_CR15","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrmicro1662","volume":"5","author":"MM Levine","year":"2007","unstructured":"Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol. 2007;5:540\u201353.","journal-title":"Nat Rev Microbiol"},{"key":"1780_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1128\/AAC.48.2.681-684.2004","volume":"48","author":"GP Pazhani","year":"2004","unstructured":"Pazhani GP, Sarkar B, Ramamurthy T, Bhattacharya S, Takeda Y, Niyogi S. Clonal multidrug-resistant Shigella dysenteriae type 1 strains associated with epidemic and sporadic dysenteries in eastern India. Antimicrob Agents Chemother. 2004;48:681\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"1780_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1017\/S0950268811000525","volume":"140","author":"A El-Gendy","year":"2012","unstructured":"El-Gendy A, Mansour A, Weiner M, Pimentel G, Armstrong A, Young S, Elsayed N, Klena J. Genetic diversity and antibiotic resistance in Shigella dysenteriae and Shigella boydii strains isolated from children aged < 5 years in Egypt. Epidemiol Infect. 2012;140:299\u2013310.","journal-title":"Epidemiol Infect"},{"key":"1780_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-03949-8","volume":"9","author":"KS Baker","year":"2018","unstructured":"Baker KS, Dallman TJ, Field N, Childs T, Mitchell H, Day M, Weill F-X, Lef\u00e8vre S, Tourdjman M, Hughes G. Horizontal antimicrobial resistance transfer drives epidemics of multiple Shigella species. Nat Commun. 2018;9:1\u201310.","journal-title":"Nat Commun"},{"key":"1780_CR19","first-page":"1","volume":"1","author":"E Njamkepo","year":"2016","unstructured":"Njamkepo E, Fawal N, Tran-Dien A, Hawkey J, Strockbine N, Jenkins C, Talukder KA, Bercion R, Kuleshov K, Kol\u00ednsk\u00e1 R. Global phylogeography and evolutionary history of Shigella dysenteriae type 1. Nat Microbiol. 2016;1:1\u201310.","journal-title":"Nat Microbiol"},{"key":"1780_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nrgastro.2013.12","volume":"10","author":"EM Barry","year":"2013","unstructured":"Barry EM, Pasetti MF, Sztein MB, Fasano A, Kotloff KL, Levine MM. Progress and pitfalls in Shigella vaccine research. Nat Rev Gastroenterol Hepatol. 2013;10:245.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1780_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/B978-0-12-811924-2.00030-4","volume-title":"Mucosal vaccines","author":"MF Pasetti","year":"2020","unstructured":"Pasetti MF, Venkatesan MM, Barry EM. Chapter 30\u2014oral Shigella vaccines. In: Kiyono H, Pascual DW editors. Mucosal vaccines. 2nd ed. Academic Press; 2020. p. 515\u201336.","edition":"2"},{"key":"1780_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1128\/CMR.00032-07","volume":"21","author":"GN Schroeder","year":"2008","unstructured":"Schroeder GN, Hilbi H. Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. Clin Microbiol Rev. 2008;21:134\u201356.","journal-title":"Clin Microbiol Rev"},{"key":"1780_CR23","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1128\/IAI.06174-11","volume":"80","author":"FJ Martinez-Becerra","year":"2012","unstructured":"Martinez-Becerra FJ, Kissmann JM, Diaz-McNair J, Choudhari SP, Quick AM, Mellado-Sanchez G, Clements JD, Pasetti MF, Picking WL. Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infect Immun. 2012;80:1222\u201331.","journal-title":"Infect Immun"},{"key":"1780_CR24","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1016\/j.vaccine.2016.08.034","volume":"34","author":"STS Chitradevi","year":"2016","unstructured":"Chitradevi STS, Kaur G, Sivaramakrishna U, Singh D, Bansal A. Development of recombinant vaccine candidate molecule against Shigella infection. Vaccine. 2016;34:5376\u201383.","journal-title":"Vaccine"},{"key":"1780_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/icb.2015.24","volume":"93","author":"SJ Heine","year":"2015","unstructured":"Heine SJ, Franco-Mahecha OL, Chen X, Choudhari S, Blackwelder WC, Van Roosmalen ML, Leenhouts K, Picking WL, Pasetti MF. Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice. Immunol Cell Biol. 2015;93:641\u201352.","journal-title":"Immunol Cell Biol"},{"key":"1780_CR26","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.1c00345","author":"N Baruah","year":"2021","unstructured":"Baruah N, Ahamad N, Maiti S, Howlader DR, Bhaumik U, Patil VV, Chakrabarti MK, Koley H, Katti DS. Development of a self-adjuvanting, cross-protective, stable intranasal recombinant vaccine for shigellosis. ACS Infect Dis. 2021. https:\/\/doi.org\/10.1021\/acsinfecdis.1c00345.","journal-title":"ACS Infect Dis"},{"key":"1780_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00583-17","author":"KR Turbyfill","year":"2018","unstructured":"Turbyfill KR, Clarkson KA, Vortherms AR, Oaks EV, Kaminski RW. Assembly, biochemical characterization, immunogenicity, adjuvanticity, and efficacy of Shigella artificial invaplex. Msphere. 2018. https:\/\/doi.org\/10.1128\/mSphere.00583-17.","journal-title":"Msphere"},{"key":"1780_CR28","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.xphs.2016.05.015","volume":"105","author":"AR Bernard","year":"2016","unstructured":"Bernard AR, Duarte SM, Kumar P, Dickenson NE. Detergent isolation stabilizes and activates the Shigella type III secretion system translocator protein IpaC. J Pharm Sci. 2016;105:2240\u20138.","journal-title":"J Pharm Sci"},{"key":"1780_CR29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14760584.2017.1306441","volume":"16","author":"S Scheiblhofer","year":"2017","unstructured":"Scheiblhofer S, Laimer J, Machado Y, Weiss R, Thalhamer J. Influence of protein fold stability on immunogenicity and its implications for vaccine design. Expert Rev Vaccines. 2017;16:479\u201389.","journal-title":"Expert Rev Vaccines"},{"key":"1780_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.mib.2009.12.001","volume":"13","author":"AC Rice-Ficht","year":"2010","unstructured":"Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA. Polymeric particles in vaccine delivery. Curr Opin Microbiol. 2010;13:106\u201312.","journal-title":"Curr Opin Microbiol"},{"key":"1780_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","volume":"75","author":"A Kumari","year":"2010","unstructured":"Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf, B. 2010;75:1\u201318.","journal-title":"Colloids Surf, B"},{"key":"1780_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41565-020-00790-3","volume":"16","author":"A Singh","year":"2021","unstructured":"Singh A. Eliciting B cell immunity against infectious diseases using nanovaccines. Nat Nanotechnol. 2021;16:16\u201324.","journal-title":"Nat Nanotechnol"},{"key":"1780_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/12_2011_150","volume-title":"Polymers in nanomedicine","author":"T Akagi","year":"2011","unstructured":"Akagi T, Baba M, Akashi M. Biodegradable nanoparticles as vaccine adjuvants and delivery systems: regulation of immune responses by nanoparticle-based vaccine. In: Kunugi S, Yamaoka T, editors. Polymers in nanomedicine. Berlin: Springer; 2011. p. 31\u201364."},{"key":"1780_CR34","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.3389\/fimmu.2018.02224","volume":"9","author":"R Pati","year":"2018","unstructured":"Pati R, Shevtsov M, Sonawane A. Nanoparticle vaccines against infectious diseases. Front Immunol. 2018;9:2224.","journal-title":"Front Immunol"},{"key":"1780_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2020.111684","volume":"120","author":"OA Tosyali","year":"2021","unstructured":"Tosyali OA, Allahverdiyev A, Bagirova M, Abamor ES, Aydogdu M, Dinparvar S, Acar T, Mustafaeva Z, Derman S. Nano-co-delivery of lipophosphoglycan with soluble and autoclaved leishmania antigens into PLGA nanoparticles: evaluation of in vitro and in vivo immunostimulatory effects against visceral leishmaniasis. Mater Sci Eng, C. 2021;120: 111684.","journal-title":"Mater Sci Eng, C"},{"key":"1780_CR36","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1007\/s11095-014-1419-y","volume":"31","author":"P Sahdev","year":"2014","unstructured":"Sahdev P, Ochyl LJ, Moon JJ. Biomaterials for nanoparticle vaccine delivery systems. Pharm Res. 2014;31:2563\u201382.","journal-title":"Pharm Res"},{"key":"1780_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jconrel.2019.05.003","volume":"304","author":"K Park","year":"2019","unstructured":"Park K, Skidmore S, Hadar J, Garner J, Park H, Otte A, Soh BK, Yoon G, Yu D, Yun Y. Injectable, long-acting PLGA formulations: analyzing PLGA and understanding microparticle formation. J Control Release. 2019;304:125\u201334.","journal-title":"J Control Release"},{"key":"1780_CR38","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1080\/21645515.2015.1117714","volume":"12","author":"A Silva","year":"2016","unstructured":"Silva A, Soema P, Sl\u00fctter B, Ossendorp F, Jiskoot W. PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity. Hum Vaccin Immunother. 2016;12:1056\u201369.","journal-title":"Hum Vaccin Immunother"},{"key":"1780_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jconrel.2014.08.029","volume":"196","author":"RB Shah","year":"2014","unstructured":"Shah RB, Schwendeman SP. A biomimetic approach to active self-microencapsulation of proteins in PLGA. J Control Release. 2014;196:60\u201370.","journal-title":"J Control Release"},{"key":"1780_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.biomaterials.2016.03.039","volume":"97","author":"AL Siefert","year":"2016","unstructured":"Siefert AL, Caplan MJ, Fahmy TM. Artificial bacterial biomimetic nanoparticles synergize pathogen-associated molecular patterns for vaccine efficacy. Biomaterials. 2016;97:85\u201396.","journal-title":"Biomaterials"},{"key":"1780_CR41","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Pr\u00e9at V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505\u201322.","journal-title":"J Control Release"},{"key":"1780_CR42","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3:1377\u201397.","journal-title":"Polymers"},{"key":"1780_CR43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jconrel.2009.10.033","volume":"142","author":"TE Rajapaksa","year":"2010","unstructured":"Rajapaksa TE, Stover-Hamer M, Fernandez X, Eckelhoefer HA, Lo DD. Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J Control Release. 2010;142:196\u2013205.","journal-title":"J Control Release"},{"key":"1780_CR44","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/0264-410X(91)90295-H","volume":"9","author":"D O'Hagan","year":"1991","unstructured":"O\u2019Hagan D, Jeffery H, Roberts M, McGee J, Davis S. Controlled release microparticles for vaccine development. Vaccine. 1991;9:768\u201371.","journal-title":"Vaccine"},{"key":"1780_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2019.115813","volume":"232","author":"F Gilavand","year":"2020","unstructured":"Gilavand F, Marzban A, Ebrahimipour G, Soleimani N, Goudarzi M. Designation of chitosan nano-vaccine based on MxiH antigen of Shigella flexneri with increased immunization capacity. Carbohyd Polym. 2020;232: 115813.","journal-title":"Carbohyd Polym"},{"key":"1780_CR46","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1016\/j.vaccine.2013.05.020","volume":"31","author":"AI Camacho","year":"2013","unstructured":"Camacho AI, Irache JM, de Souza J, S\u00e1nchez-G\u00f3mez S, Gamazo C. Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice. Vaccine. 2013;31:3288\u201394.","journal-title":"Vaccine"},{"key":"1780_CR47","first-page":"212","volume":"16","author":"MR Akbari","year":"2019","unstructured":"Akbari MR, Saadati M, Honari H, Ghorbani HM. IpaD-loaded N-trimethyl chitosan nanoparticles can efficiently protect guinea pigs against Shigella flexneri. Iran J Immunol. 2019;16:212\u201324.","journal-title":"Iran J Immunol"},{"key":"1780_CR48","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1021\/acs.molpharmaceut.2c00378","volume":"19","author":"N Baruah","year":"2022","unstructured":"Baruah N, Halder P, Koley H, Katti DS. Stable recombinant Invasion plasmid antigen C (IpaC)-based single dose nanovaccine for shigellosis. Mol Pharm. 2022;19:3884\u201393.","journal-title":"Mol Pharm"},{"key":"1780_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1208\/s12248-012-9418-6","volume":"15","author":"VB Joshi","year":"2013","unstructured":"Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine delivery systems: size matters. AAPS J. 2013;15:85\u201394.","journal-title":"AAPS J"},{"key":"1780_CR50","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1002\/smll.201503662","volume":"12","author":"Q Liu","year":"2016","unstructured":"Liu Q, Jia J, Yang T, Fan Q, Wang L, Ma G. Pathogen-mimicking polymeric nanoparticles based on dopamine polymerization as vaccines adjuvants induce robust humoral and cellular immune responses. Small. 2016;12:1744\u201357.","journal-title":"Small"},{"key":"1780_CR51","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1016\/j.biomaterials.2005.03.043","volume":"26","author":"SP Kasturi","year":"2005","unstructured":"Kasturi SP, Sachaphibulkij K, Roy K. Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines. Biomaterials. 2005;26:6375\u201385.","journal-title":"Biomaterials"},{"key":"1780_CR52","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.4049\/jimmunol.1000768","volume":"185","author":"SL Demento","year":"2010","unstructured":"Demento SL, Bonaf\u00e9 N, Cui W, Kaech SM, Caplan MJ, Fikrig E, Ledizet M, Fahmy TM. TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J Immunol. 2010;185:2989\u201397.","journal-title":"J Immunol"},{"key":"1780_CR53","doi-asserted-by":"publisher","first-page":"9743","DOI":"10.1021\/nn403085w","volume":"7","author":"NM Molino","year":"2013","unstructured":"Molino NM, Anderson AK, Nelson EL, Wang S-W. Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation. ACS Nano. 2013;7:9743\u201352.","journal-title":"ACS Nano"},{"key":"1780_CR54","doi-asserted-by":"publisher","first-page":"8996","DOI":"10.1002\/anie.201807779","volume":"58","author":"X Liu","year":"2019","unstructured":"Liu X, Zhao Y, Liu P, Wang L, Lin J, Fan C. Biomimetic DNA nanotubes: nanoscale channel design and applications. Angew Chem Int Ed. 2019;58:8996\u20139011.","journal-title":"Angew Chem Int Ed"},{"key":"1780_CR55","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1002\/anie.201200048","volume":"51","author":"BG De Geest","year":"2012","unstructured":"De Geest BG, Willart MA, Lambrecht BN, Pollard C, Vervaet C, Remon JP, Grooten J, De Koker S. Surface-engineered polyelectrolyte multilayer capsules: synthetic vaccines mimicking microbial structure and function. Angew Chem Int Ed. 2012;51:3862\u20136.","journal-title":"Angew Chem Int Ed"},{"key":"1780_CR56","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/erv.10.174","volume":"10","author":"C Bode","year":"2011","unstructured":"Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2011;10:499\u2013511.","journal-title":"Expert Rev Vaccines"},{"key":"1780_CR57","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.addr.2008.12.012","volume":"61","author":"DM Klinman","year":"2009","unstructured":"Klinman DM, Klaschik S, Sato T, Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev. 2009;61:248\u201355.","journal-title":"Adv Drug Deliv Rev"},{"key":"1780_CR58","doi-asserted-by":"publisher","first-page":"19902","DOI":"10.1073\/pnas.1313152110","volume":"110","author":"A De Titta","year":"2013","unstructured":"De Titta A, Ballester M, Julier Z, Nembrini C, Jeanbart L, Van Der Vlies AJ, Swartz MA, Hubbell JA. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci USA. 2013;110:19902\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1780_CR59","doi-asserted-by":"publisher","first-page":"9603","DOI":"10.1039\/C9NR09782A","volume":"12","author":"R Khalifehzadeh","year":"2020","unstructured":"Khalifehzadeh R, Arami H. The CpG molecular structure controls the mineralization of calcium phosphate nanoparticles and their immunostimulation efficacy as vaccine adjuvants. Nanoscale. 2020;12:9603\u201315.","journal-title":"Nanoscale"},{"key":"1780_CR60","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1586\/14760584.6.5.797","volume":"6","author":"M Singh","year":"2007","unstructured":"Singh M, Chakrapani A, O\u2019Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines. 2007;6:797\u2013808.","journal-title":"Expert Rev Vaccines"},{"key":"1780_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000271","volume":"5","author":"J Mounier","year":"2009","unstructured":"Mounier J, Popoff MR, Enninga J, Frame MC, Sansonetti PJ, Van Nhieu GT. The IpaC carboxyterminal effector domain mediates Src-dependent actin polymerization during Shigella invasion of epithelial cells. PLoS Pathogen. 2009;5: e1000271.","journal-title":"PLoS Pathogen"},{"key":"1780_CR62","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1093\/emboj\/18.12.3249","volume":"18","author":"GT Van Nhieu","year":"1999","unstructured":"Van Nhieu GT, Caron E, Hall A, Sansonetti PJ. IpaC induces actin polymerization and filopodia formation during Shigella entry into epithelial cells. EMBO J. 1999;18:3249\u201362.","journal-title":"EMBO J"},{"key":"1780_CR63","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1073\/pnas.93.3.1254","volume":"93","author":"R M\u00e9nard","year":"1996","unstructured":"M\u00e9nard R, Pr\u00e9vost M-C, Gounon P, Sansonetti P, Dehio C. The secreted Ipa complex of Shigella flexneri promotes entry into mammalian cells. Proc Natl Acad Sci USA. 1996;93:1254\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1780_CR64","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/17425247.2020.1731468","volume":"17","author":"M Skwarczynski","year":"2020","unstructured":"Skwarczynski M, Toth I. Non-invasive mucosal vaccine delivery: advantages, challenges and the future. Expert Opin Drug Deliv. 2020;17:435\u20137.","journal-title":"Expert Opin Drug Deliv"},{"key":"1780_CR65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0169-409X(01)00162-4","volume":"51","author":"S Davis","year":"2001","unstructured":"Davis S. Nasal vaccines. Adv Drug Deliv Rev. 2001;51:21\u201342.","journal-title":"Adv Drug Deliv Rev"},{"key":"1780_CR66","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","volume":"3","author":"PG Djupesland","year":"2013","unstructured":"Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective\u2014a review. Drug Deliv Transl Res. 2013;3:42\u201362.","journal-title":"Drug Deliv Transl Res"},{"key":"1780_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1023\/B:PHAR.0000026823.82950.ff","volume":"26","author":"S T\u00fcrker","year":"2004","unstructured":"T\u00fcrker S, Onur E, \u00d3zer Y. Nasal route and drug delivery systems. Pharm World Sci. 2004;26:137\u201342.","journal-title":"Pharm World Sci"},{"key":"1780_CR68","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1586\/14760584.4.2.185","volume":"4","author":"M K\u00f6ping-H\u00f6gg\u00e5rd","year":"2005","unstructured":"K\u00f6ping-H\u00f6gg\u00e5rd M, S\u00e1nchez A, Alonso MJ. Nanoparticles as carriers for nasal vaccine delivery. Expert Rev Vaccines. 2005;4:185\u201396.","journal-title":"Expert Rev Vaccines"},{"key":"1780_CR69","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF02786362","volume":"16","author":"H-Y Wu","year":"1997","unstructured":"Wu H-Y, Russell MW. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol Res. 1997;16:187\u2013201.","journal-title":"Immunol Res"},{"key":"1780_CR70","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.mimet.2016.05.014","volume":"127","author":"N Ahamad","year":"2016","unstructured":"Ahamad N, Katti DS. A two-step method for extraction of lipopolysaccharide from Shigella dysenteriae serotype 1 and Salmonella typhimurium: an improved method for enhanced yield and purity. J Microbiol Methods. 2016;127:41\u201350.","journal-title":"J Microbiol Methods"},{"key":"1780_CR71","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/cmi.2014.86","volume":"12","author":"STS Chitradevi","year":"2015","unstructured":"Chitradevi STS, Kaur G, Uppalapati S, Yadav A, Singh D, Bansal A. Co-administration of rIpaB domain of Shigella with rGroEL of S. Typhi enhances the immune responses and protective efficacy against Shigella infection. Cell Mol Immunol. 2015;12:757\u201367.","journal-title":"Cell Mol Immunol"},{"key":"1780_CR72","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0168-3659(97)00106-5","volume":"50","author":"M Zambaux","year":"1998","unstructured":"Zambaux M, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso M, Labrude P, Vigneron C. Influence of experimental parameters on the characteristics of poly (lactic acid) nanoparticles prepared by a double emulsion method. J Control Release. 1998;50:31\u201340.","journal-title":"J Control Release"},{"key":"1780_CR73","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0168-3659(96)01484-8","volume":"43","author":"C Song","year":"1997","unstructured":"Song C, Labhasetwar V, Murphy H, Qu X, Humphrey W, Shebuski R, Levy R. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J Control Release. 1997;43:197\u2013212.","journal-title":"J Control Release"},{"key":"1780_CR74","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1023\/A:1018980020506","volume":"10","author":"H Jeffery","year":"1993","unstructured":"Jeffery H, Davis SS, O\u2019Hagan DT. The preparation and characterization of poly (lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm Res. 1993;10:362\u20138.","journal-title":"Pharm Res"},{"key":"1780_CR75","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"1780_CR76","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"1780_CR77","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1182\/blood-2009-07-230631","volume":"115","author":"K Maeda","year":"2010","unstructured":"Maeda K, Mehta H, Drevets DA, Coggeshall KM. IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production. Blood. 2010;115:4699\u2013706.","journal-title":"Blood"},{"key":"1780_CR78","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.4049\/jimmunol.164.4.2221","volume":"164","author":"T Samandari","year":"2000","unstructured":"Samandari T, Kotloff KL, Losonsky GA, Picking WD, Sansonetti PJ, Levine MM, Sztein MB. Production of IFN-\u03b3 and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a shiga toxin-deleted Shigella dysenteriae type 1 strain. J Immunol. 2000;164:2221\u201332.","journal-title":"J Immunol"},{"key":"1780_CR79","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1128\/IAI.00859-13","volume":"81","author":"FJ Martinez-Becerra","year":"2013","unstructured":"Martinez-Becerra FJ, Chen X, Dickenson NE, Choudhari SP, Harrison K, Clements JD, Picking WD, Van De Verg LL, Walker RI, Picking WL. Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine. Infect Immun. 2013;81:4470\u20137.","journal-title":"Infect Immun"},{"key":"1780_CR80","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/infdis\/jit399","volume":"209","author":"J-Y Yang","year":"2013","unstructured":"Yang J-Y, Lee S-N, Chang S-Y, Ko H-J, Ryu S, Kweon M-N. A mouse model of shigellosis by intraperitoneal infection. J Infect Dis. 2013;209:203\u201315.","journal-title":"J Infect Dis"},{"key":"1780_CR81","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1080\/21645515.2019.1606972","volume":"15","author":"L-A Barel","year":"2019","unstructured":"Barel L-A, Mulard LA. Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human. Hum Vaccin Immunother. 2019;15:1338\u201356.","journal-title":"Hum Vaccin Immunother"},{"key":"1780_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715393","author":"F Mancini","year":"2021","unstructured":"Mancini F, Micoli F, Necchi F, Pizza M, Berlanda Scorza F, Rossi O. GMMA-based vaccines: the known and the unknown. Front Immun. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.715393.","journal-title":"Front Immun"},{"key":"1780_CR83","doi-asserted-by":"publisher","first-page":"8222","DOI":"10.1016\/j.vaccine.2011.08.121","volume":"29","author":"A Camacho","year":"2011","unstructured":"Camacho A, De Souza J, S\u00e1nchez-G\u00f3mez S, Pardo-Ros M, Irache JM, Gamazo C. Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice. Vaccine. 2011;29:8222\u20139.","journal-title":"Vaccine"},{"key":"1780_CR84","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1574-695X.2012.01004.x","volume":"66","author":"S Mitra","year":"2012","unstructured":"Mitra S, Barman S, Nag D, Sinha R, Saha DR, Koley H. Outer membrane vesicles of Shigella boydii type 4 induce passive immunity in neonatal mice. FEMS Immunol Med Microbiol. 2012;66:240\u201350.","journal-title":"FEMS Immunol Med Microbiol"},{"key":"1780_CR85","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1016\/j.vaccine.2013.05.001","volume":"31","author":"S Mitra","year":"2013","unstructured":"Mitra S, Chakrabarti MK, Koley H. Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis. Vaccine. 2013;31:3163\u201373.","journal-title":"Vaccine"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01780-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-023-01780-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01780-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T22:04:48Z","timestamp":1675116288000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-023-01780-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,29]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1780"],"URL":"https:\/\/doi.org\/10.1186\/s12951-023-01780-y","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,29]]},"assertion":[{"value":"22 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors (NB and DSK) declare that they have filed an Indian patent (IN202111046357). The remaining authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}